CAJ | 학술논문

目的观察埃罗替尼治疗晚期非小细胞肺癌的疗效及不良反应.方法 35例放化疗失败的非小细胞肺癌患者,服用埃罗替尼150 mg/次,每日1次,直至肿瘤进展或出现不可耐受的不良反应.全组服用中位时间为6个月.按WHO标准评价疗效及不良反应.结果 35例可评价病例中完全缓解0例,部分缓解10例,稳定14例,病情进展11例,有效率28.6％,症状缓解率超过50.0％.中位生存期6.6个月,无进展生存期(PFS)为4.5个月(1.5～23个月),1年生存率31.4％.主要不良反应是皮疹(60.0％)和腹泻(48.6％).结论埃罗替尼对晚期非小细胞肺癌有明显的抗肿瘤作用,是一种有效且具有良好耐性的靶向治疗药物.
목적 관찰애라체니치료만기비소세포폐암적료효급불량반응.방법 35례방화료실패적비소세포폐암환자,복용애라체니150 mg/차,매일1차,직지종류진전혹출현불가내수적불량반응.전조복용중위시간위6개월.안WHO표준평개료효급불량반응.결과 35례가평개병례중완전완해0례,부분완해10례,은정14례,병정진전11례,유효솔28.6％,증상완해솔초과50.0％.중위생존기6.6개월,무진전생존기(PFS)위4.5개월(1.5～23개월),1년생존솔31.4％.주요불량반응시피진(60.0％)화복사(48.6％).결론 애라체니대만기비소세포폐암유명현적항종류작용,시일충유효차구유량호내성적파향치료약물.
Objective To observe the result and side effects of eriotinib in patients with advanced non - smarapy in patients with NSCLC,oraling eriotinib 150 mg/time,once daily,until disease progression or the occurrence of intolerable toxicity.The median time of eriotinib was 6 months.According to WHO criteria to evaluate the efficacy and side effects.Results Among the 35 patients,none got complete response,partial response in 10 cases,stable in 14 cases,progress of the disease in 11 cases,efficiency was 28.6％,symptom relief rate more than 50.0％.The median survival time was 6.6 months,progression - free survival (PFS) was 4.5 months,1 - year survival rate was 31.4％.The main side effects were rash ( 60.0％ ) and diarrhea (48.6％).Conclusions Eriotinib for NSCLC has obvious anti -tumor effect,is an effective and targeted therapy with good tolerance to drugs.